Capvaxive uniquely adds eight adult-predominant invasive serotypes absent from other approved pneumococcal vaccines, ...
Additive manufacturing allows pharma and biotech companies to take advantage of 3D printing technology to produce medications ...
As Connecticut moves to rein in private equity's playbook in hospital deals, pharma and life sciences leaders face a parallel ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
VRBPAC voted 9-0 in both adults 50–64 and ≥65 years that mRNA-1010’s benefit–risk profile is favorable, despite FDA staff noting evidence gaps in select subpopulations. Phase III efficacy data showed ...
A rare tumor launch using claims plus behavioral triggers and KOL-balanced content exceeded forecasts, attributing 60% of new ...
Kardigan’s offering proposes 23.3 million shares at $14–$16, targeting ~$350 million gross proceeds and an implied ~$1.3 ...
Silvia Taylor of Novavax details how the company leverages its expertise in vaccine development to build partnerships across ...
Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, explains why shifting the conversation from simple ...
FDA approved Utebzi, an oral carbapenem antibiotic developed by GSK in partnership with Spero Therapeutics, for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis in ...
Bexobrutideg leverages targeted protein degradation to eliminate BTK, potentially overcoming resistance mutations and ...
In January of this year, Novavax announced a partnership that would provide its Matrix-M adjuvant technology to Pfizer for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results